Levosimendan in patients with decompensated heart failure.
作者信息
Rosa Eduardo Maffini da, Osório Ana Paula Susin, Scopel Luciano
出版信息
Arq Bras Cardiol. 2008 Aug;91(2):119. doi: 10.1590/s0066-782x2008001400010.
Abstract
摘要
相似文献
1
Levosimendan in patients with decompensated heart failure.
Arq Bras Cardiol. 2008 Aug;91(2):119. doi: 10.1590/s0066-782x2008001400010.
2
Can we believe in levosimendan?
Arq Bras Cardiol. 2008 Mar;90(3):146-7. doi: 10.1590/s0066-782x2008000300001.
3
BELIEF: believe it or not.
Arq Bras Cardiol. 2008 Aug;91(2):119-21. doi: 10.1590/s0066-782x2008001400011.
4
Levosimendan use in several scenarios of acute heart failure.
Arq Bras Cardiol. 2008 Mar;90(3):211-5. doi: 10.1590/s0066-782x2008000300012.
5
Heart failure update.
Eur J Heart Fail. 1999 Aug;1(3):301-2. doi: 10.1016/s1388-9842(99)00040-9.
6
Safety and efficacy of levosimendan in patients with cardiac amyloidosis.
Eur J Intern Med. 2020 Oct;80:114-116. doi: 10.1016/j.ejim.2020.06.037. Epub 2020 Jul 3.
7
Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
Curr Cardiol Rep. 2000 May;2(3):233-43. doi: 10.1007/s11886-000-0074-6.
8
Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
Int J Cardiol. 2005 Oct 10;104(3):355-6; author reply 357-8. doi: 10.1016/j.ijcard.2005.04.035. Epub 2005 Jun 9.
9
Positive inotropy for acute heart failure complicating myocardial infarction.
Eur Heart J. 2002 Sep;23(18):1405-6. doi: 10.1053/euhj.2002.3297.
10
Levosimendan as a bridge to heart transplant: a real alternative.
Rev Esp Cardiol (Engl Ed). 2024 Apr;77(4):302-303. doi: 10.1016/j.rec.2023.10.011. Epub 2023 Dec 15.
Zotero 插件